PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
Oncology
Prevalence
256.0 / 100K
Incidence
111.0 / 100K/yr
2 drugs in development·1 company·2 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| HRS-4357 injection | KYNTRA BIO INC. (KYNB) |
Phase 4(1)
Compare drugs
Frequently asked questions
How many drugs are in development for PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer?
BioSniper tracks 2 drugs in development for PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer across 1 company.
How many clinical trials target PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer?
There are 2 clinical trials targeting PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer tracked by BioSniper.
What is the prevalence of PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer?
The estimated prevalence of PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer is approximately 256.0 per 100,000 population.
Deep-dive into PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis